MAPT and Alzheimer disease: Transgenic AD models, while accurately mimicking key features like Aβ deposition and Tau hyperphosphorylation, have significant drawbacks, including a long latency for the appearance of pathology (6–9 months) and complex, time-consuming breeding processes.